Safety and immunogenicity testing of a melioidosis subunit vaccine candidate in cynomolgus macaques

npj Vaccines · Published 2026-07-14 · DOI 10.1038/s41541-026-01526-5

Free full text

Authors (11)

Sineenart Sengyee, Caitlyn E. Orne, Sarah B. Weiby, Lindsey K. Schmidt, Federico Urbano-Munoz, Jiri Vlach, Christian Heiss, Parastoo Azadi, Narisara Chantratita, Mary N. Burtnick, Paul J. Brett

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Sengyee, S., Orne, C., Weiby, S., et al. (2026). Safety and immunogenicity testing of a melioidosis subunit vaccine candidate in cynomolgus macaques. npj Vaccines. https://doi.org/10.1038/s41541-026-01526-5

Related articles

• Maturation-deficient chikungunya virus elicits protective immune responses in a murine challenge model · npj Vaccines · 2026 · Same journal
• Recent advances in Epstein–Barr virus vaccines development from mechanistic exploration to clinical translation · npj Vaccines · 2026 · Same journal
• Maternal influenza vaccination boosts durable breast milk antibody-mediated protection in infants · npj Vaccines · 2026 · Same journal
• Vaccination in individuals with Down syndrome: immune vulnerability, safety, efficacy and opportunities · npj Vaccines · 2026 · Same journal
• Preserved SARS-CoV-2 T-cell responses despite impaired humoral immunity in children with profound B-cell lymphopenia · npj Vaccines · 2026 · Same journal
• Suppressor tRNA-mediated conditionally replicating live vaccine effectively protects pigs against Seneca Valley virus challenge · npj Vaccines · 2026 · Same journal
• Long-term cross-variant Fc-mediated immune responses against SARS-CoV-2 induced by a heterologous adenoviral/inactivated virus prime-boost vaccination strategy · npj Vaccines · 2026 · Same journal
• Post-exposure vaccination with an adjuvanted protein subunit vaccine, but not BCG, protects mice and guinea pigs against M. tuberculosis · npj Vaccines · 2026 · Same journal
• Multiorgan Outcomes Following BNT162b2 mRNA Vaccination vs SARS-CoV-2 Infection: A 30-Million-Person Real-World Cohort Analysis · npj Vaccines · 2026 · Same journal
• Modeling time-varying efficacy of RTS,S/AS01 malaria vaccine across trial settings · npj Vaccines · 2026 · Same journal